{"@context":"https://schema.org","@graph":[{"@type":["Organization","MedicalOrganization"],"@id":"https://www.innocarepharma.com/#organization","name":"诺诚健华","alternateName":["InnoCare","InnoCare Pharma","诺诚健华医药"],"url":"https://www.innocarepharma.com","logo":"https://www.innocarepharma.com/static/logo2.png","sameAs":["https://www.hkex.com.hk/","https://www.sse.com.cn/"],"description":"诺诚健华是一家专注于恶性肿瘤及自身免疫性疾病创新药研发、生产及商业化的生物医药企业。"},{"@type":"Person","name":"陈向阳 博士","jobTitle":"首席技术官","description":"","worksFor":{"@type":"Organization","name":"诺诚健华"}},{"@type":"Person","name":"陈少峰","jobTitle":"首席商务官","description":"","worksFor":{"@type":"Organization","name":"诺诚健华"}},{"@type":"Person","name":"高楠 博士","jobTitle":"首席运营官","description":"","worksFor":{"@type":"Organization","name":"诺诚健华"}},{"@type":"Person","name":"刘瑞勤 博士","jobTitle":"新药研究副总裁","description":"","worksFor":{"@type":"Organization","name":"诺诚健华"}},{"@type":"Person","name":"王英 博士","jobTitle":"药物安全及药代药动副总裁","description":"","worksFor":{"@type":"Organization","name":"诺诚健华"}},{"@type":"Person","name":"赵仁滨 博士","jobTitle":"血液瘤医学研究和临床开发高级副总裁","description":"","worksFor":{"@type":"Organization","name":"诺诚健华"}},{"@type":"Person","name":"孔祥龙 博士","jobTitle":"药物化学副总裁","description":"","worksFor":{"@type":"Organization","name":"诺诚健华"}},{"@type":"Person","name":"张伯彦 博士","jobTitle":"大分子CMC副总裁","description":"","worksFor":{"@type":"Organization","name":"诺诚健华"}},{"@type":"Person","name":"周伟 博士","jobTitle":"医学研究副总裁","description":"","worksFor":{"@type":"Organization","name":"诺诚健华"}},{"@type":"Person","name":"王俊苏","jobTitle":"总法务顾问","description":"","worksFor":{"@type":"Organization","name":"诺诚健华"}},{"@type":"MedicalTherapy","name":"奥布替尼","description":"奥布替尼 targeting <p>BTK</p> for r/r CLL/SLL","indication":"r/r CLL/SLL","adverseOutcome":"已上市"},{"@type":"MedicalTherapy","name":"奥布替尼","description":"奥布替尼 targeting <p>BTK</p> for r/r MCL","indication":"r/r MCL","adverseOutcome":"已上市"},{"@type":"MedicalTherapy","name":"奥布替尼","description":"奥布替尼 targeting <p>BTK\t</p> for r/r MZL","indication":"r/r MZL","adverseOutcome":"已上市"},{"@type":"MedicalTherapy","name":"奥布替尼","description":"奥布替尼 targeting <p>BTK\t</p> for 1L: CLL/SLL\t","indication":"1L: CLL/SLL\t","adverseOutcome":"已上市"},{"@type":"MedicalTherapy","name":"奥布替尼","description":"奥布替尼 targeting <p>BTK\t</p> for 1L: MCL","indication":"1L: MCL","adverseOutcome":"注册临床"},{"@type":"MedicalTherapy","name":"坦昔妥单抗","description":"坦昔妥单抗 targeting <p>CD19</p> for r/r DLBCL","indication":"r/r DLBCL","adverseOutcome":"已上市"},{"@type":"MedicalTherapy","name":"ICP-B02\t","description":"ICP-B02\t targeting <p>CD3xCD20</p> for CD20+B细胞血液瘤","indication":"CD20+B细胞血液瘤","adverseOutcome":"PH I"},{"@type":"MedicalTherapy","name":"Mesutoclax","description":"Mesutoclax targeting <p>BCL2</p> for 1L CLL/SLL","indication":"1L CLL/SLL","adverseOutcome":"注册临床"},{"@type":"MedicalTherapy","name":"奥布替尼","description":"奥布替尼 targeting <p>BTK\t</p> for SLE","indication":"SLE","adverseOutcome":"注册临床"},{"@type":"MedicalTherapy","name":"奥布替尼","description":"奥布替尼 targeting <p>BTK\t</p> for SPMS","indication":"SPMS","adverseOutcome":"注册临床（全球）"},{"@type":"MedicalTherapy","name":"奥布替尼","description":"奥布替尼 targeting <p>BTK\t</p> for ITP","indication":"ITP","adverseOutcome":"上市申请获受理"},{"@type":"MedicalTherapy","name":"Soficitinib","description":"Soficitinib targeting <p>TYK2-JH1</p> for AD","indication":"AD","adverseOutcome":"注册临床"},{"@type":"MedicalTherapy","name":"Fadeucravacitinib","description":"Fadeucravacitinib targeting <p>TYK2-JH2</p> for 银屑病","indication":"银屑病","adverseOutcome":"注册临床"},{"@type":"MedicalTherapy","name":"佐来曲替尼","description":"佐来曲替尼 targeting <p>NTRK</p> for NTRK融合阳性肿瘤（成年人及青少年患者）","indication":"NTRK融合阳性肿瘤（成年人及青少年患者）","adverseOutcome":"已上市"},{"@type":"MedicalTherapy","name":"佐来曲替尼","description":"佐来曲替尼 targeting <p>NTRK</p> for NTRK融合阳性肿瘤（儿童患者）","indication":"NTRK融合阳性肿瘤（儿童患者）","adverseOutcome":"上市申请获受理"},{"@type":"MedicalTherapy","name":"ICP-B794","description":"ICP-B794 targeting <p>B7-H3</p> for 实体瘤","indication":"实体瘤","adverseOutcome":"PH I"},{"@type":"MedicalTherapy","name":"Mesutoclax","description":"Mesutoclax targeting <p>BCL2</p> for BTKi Failure r/r MCL","indication":"BTKi Failure r/r MCL","adverseOutcome":"注册临床"},{"@type":"MedicalTherapy","name":"Mesutoclax","description":"Mesutoclax targeting <p>BCL2</p> for 1L AML","indication":"1L AML","adverseOutcome":"PH I/II"},{"@type":"MedicalTherapy","name":"Mesutoclax","description":"Mesutoclax targeting <p>BCL2</p> for MDS","indication":"MDS","adverseOutcome":"PH I/II"},{"@type":"MedicalTherapy","name":"奥布替尼","description":"奥布替尼 targeting <p>BTK</p> for PPMS","indication":"PPMS","adverseOutcome":"注册临床（全球）"}]}